MedPath
FDA Approval

BESREMi

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
PharmaEssentia USA
DUNS: 080514277
Effective Date
January 12, 2024
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Ropeginterferon alfa-2b(500 ug in 1 mL)

Manufacturing Establishments2

FDA-registered manufacturing facilities and establishments involved in the production, packaging, or distribution of this drug product.

PharmaEssentia Corporation, Taichung Plant

PharmaEssentia USA

658873411

PYRAMID Laboratories, Inc.

PharmaEssentia USA

783409162

Products1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

BESREMi

Product Details

NDC Product Code
73536-500
Application Number
BLA761166
Marketing Category
BLA (C73585)
Route of Administration
SUBCUTANEOUS
Effective Date
January 12, 2024
BENZYL ALCOHOLInactive
Code: LKG8494WBHClass: IACTQuantity: 10 mg in 1 mL
ACETIC ACIDInactive
Code: Q40Q9N063PClass: IACT
POLYSORBATE 80Inactive
Code: 6OZP39ZG8HClass: IACT
SODIUM ACETATEInactive
Code: 4550K0SC9BClass: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8XClass: IACT
WATERInactive
Code: 059QF0KO0RClass: IACT
Code: 981TME683SClass: ACTIBQuantity: 500 ug in 1 mL
© Copyright 2025. All Rights Reserved by MedPath